Mylan and TB Alliance Collaborate to Commercialize Pretomanid in Two Combination Regimens for Tuberculosis

Shots:

• Mylan to get manufacturing & commercialization rights of pretomanid in BPaL regimen (bedaquiline, pretomanid and linezolid for 6-9 mos.) for XDR & MDR-TB. Janssen to hold the rights for bedaquiline (Ex- DS-TB) and linezolid is available from multiple manufacturers, including Mylan
• TB Alliances has also licensed Pretomanid to Mylan for DS & MDR-TB and sublicensed bedaquiline for DS-TB only in BPaMZ regimen (bedaquiline, pretomanid, moxifloxacin and pyrazinamide for 4-6mos.)
• Pretomanid as part of the BPaL regimen is under FDA & EMA review. Mylan gets a non-exclusive & exclusive license to commercialize Pretomanid in low-& middle -income & high-income markets respectively. Janssen will retain exclusive rights to market bedaquiline as part of the combination therapy for MDR-TB

Click here to read full press release/ article | Ref: Mylan | Image: WV News